Answers are grounded in this paper and cite their sources.
Retrospective analysis shows improved survival rates in elderly patients with GBM receiving supramaximal resection and chemoradiotherapy, pointing to critical prognostic factors.
PURPOSE This study aimed to investigate clinical prognostic factors that influence postoperative survival outcomes in elderly patients (≥65 years) with newly diagnosed supratentorial lobar IDH-wildtype glioblastoma (GBM). METHODS A retrospective cohort of 69 elderly GBM patients received surgical resection between 2019 and 2023 was analyzed. Clinical, imaging, immunohistochemical, molecular and postoperative treatment-related data were systematically collected. Survival outcomes (progression-free survival [PFS] and overall survival [OS]) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models. Subgroups were stratified by postoperative chemoradiotherapy: Group 1 (no chemoradiotherapy), Group 2 (temozolomide [TMZ] only), and Group 3 (TMZ + radiotherapy). RESULTS Median PFS and OS were 7.7 and 12.13 months. Multivariate analysis revealed higher extent of resection (HR=0.623, p=0.002) and TMZ chemotherapy (HR=0.519, p=0.048) as independent protective factors for PFS. For OS, higher extent of resection (HR=0.617, p=0.001) and chemoradiotherapy (HR=0.240, p<0.001) improved survival, whereas P53 overexpression (IHC p53>10%) (HR=2.887, p=0.001) was detrimental. Moreover, elderly patients with supramaximal resection (SMR, RANO Class 1 resection) exhibited the longest PFS (12.53 vs. 9.93 vs. 7.6 vs. 5.4 vs. 1.17 months) and OS (23.07 vs. 14.6 vs. 9.87 vs. 9.8 vs. 3.4 months), and there were significant differences (p<0.001 and p=0.006, respectively). Subgroup analysis revealed significantly longer OS in Group 3 (18.53 months) versus Group 1 (7.7 months, p<0.001) and Group 2 (11.67 months, p=0.022). TMZ alone showed comparable PFS to chemoradiotherapy but inferior on OS. CONCLUSIONS SMR optimizes tumor cytoreduction in elderly GBM patients, with an increased extent of resection and TMZ chemotherapy contributing to a prolonged PFS. Moreover, an increased extent of resection and aggressive chemoradiotherapy (TMZ + radiotherapy) significantly enhance OS compared to TMZ alone or no chemoradiotherapy. However, P53 overexpression (IHC p53>10%) independently predicts poor OS. These findings support SMR followed by combined chemoradiotherapy to maximize survival in elderly GBM patients.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: